# Pfizer Research Report

**Generated:** 2025-12-09 00:10

---

# Pfizer Inc. (PFE) - Comprehensive Research Report

## Executive Summary

Pfizer Inc. demonstrates strong financial performance with full-year 2024 revenues of $63.6 billion, representing 7% year-over-year operational growth and a market capitalization of $148 billion. The pharmaceutical giant has successfully transitioned beyond its COVID-19 peak, with Q4 2024 revenues reaching $17.8 billion, a 22% increase compared to the prior-year quarter. Pfizer's strategic direction focuses on oncology expansion through its $43 billion acquisition of Seagen and development of obesity treatments, positioning the company for sustained growth in high-value therapeutic areas. The company maintains a robust pipeline of experimental drugs and recently launched products, supported by strong dividend yield of 6.61% and attractive forward P/E ratio of 8.67.

## Company Overview

### History and Founding
Pfizer Inc. was founded in 1849, making it one of the oldest pharmaceutical companies in the world with over 175 years of healthcare innovation.

### Mission/Vision
Data not available from current sources.

### Leadership Team
- **CEO**: Albert Bourla leads the company's strategic direction and global operations

### Headquarters and Global Presence
- **Headquarters**: New York, New York, United States
- **Global Operations**: Multinational presence with operations worldwide

### Employee Count
The company employs over 88,000 people globally.

## Financial Performance

### Annual Revenue and Growth
- **2024 Revenue**: $63.6 billion (7% year-over-year operational growth)
- **2023 Revenue**: $59.553 billion (41.14% decline from 2022)
- **Revenue Trend**: Pfizer annual revenue for 2024 was $63.627B, representing a 6.84% increase from 2023

### Quarterly Results
- **Q4 2024 Revenue**: $17.8 billion, an increase of $3.2 billion or 22% compared to the prior-year quarter

### Profitability Metrics
- **Earnings Per Share (TTM)**: $1.72
- **Revenue (TTM)**: $62.78B

### Key Financial Ratios
- **P/E Ratio (TTM)**: 15.13
- **Forward P/E**: 8.67
- **PEG Ratio**: 3.77
- **Price/Book**: 1.59

### Revenue by Segment
Specific segment breakdown data not available in current sources.

## Market Position

### Market Capitalization and Stock Performance
- **Market Cap**: $148.00B
- **Current Stock Price**: Data not available
- **52-Week High**: $27.21
- **52-Week Low**: $19.83
- **Exchange**: NYSE (Ticker: PFE)

### Market Share and Competitive Positioning
Pfizer operates as a leading player in the drug manufacturers - general industry within the healthcare sector.

### Valuation Metrics
- **Dividend Yield**: 6.61%
- **Sector**: Healthcare
- **Industry**: Drug Manufacturers - General

## Products & Services

### Major Product Lines
- **COVID-19 Products**: Continued revenue contribution expected in 2025 guidance
- **Oncology Portfolio**: Significantly expanded through Seagen acquisition
- **Obesity Treatments**: Portfolio of mid- and early-stage obesity assets including GLP-1s and amylins
- **mRNA Therapeutics**: Partnership with BioNTech for serious diseases including cancer, COVID-19, and malaria

### Recent Product Developments (2024-2025)
- **Pipeline Update**: Product pipeline updated as of November 4, 2025, featuring investigational medicines and vaccines
- **Obesity Assets**: Development of three obesity-focused compounds including GLP-1s, amylins, and potential combinations

### Key Services
The company focuses primarily on pharmaceutical products rather than services.

## Strategic Initiatives

### Major Acquisitions
- **Seagen Acquisition**: Completed acquisition of Seagen for $229 per share in cash, total enterprise value of approximately $43 billion, significantly expanding oncology capabilities

### R&D Focus Areas
- **Oncology**: Major investment through Seagen acquisition to battle cancer
- **Obesity Treatments**: Development of comprehensive obesity asset portfolio
- **mRNA Technology**: Continued partnership with BioNTech for therapeutic applications

### Future Investment Areas
- **Post-COVID Portfolio**: Building robust pipeline of experimental and recently launched drugs for sustained growth

## Competitive Landscape

### Main Competitors
Specific competitor analysis and market share comparisons not available in current sources.

### Competitive Advantages
- **Robust Pipeline**: Strong portfolio of experimental and recently launched drugs
- **Strategic Acquisitions**: $43 billion Seagen acquisition strengthens oncology position
- **Diversified Portfolio**: Expansion beyond COVID-19 into high-growth therapeutic areas

## Recent Developments (2024-2025)

### Major Announcements
- **Q4 2024 Results**: Strong quarterly performance with $17.8 billion in revenues
- **Seagen Acquisition Completion**: Successfully completed $43 billion acquisition
- **2025 Guidance**: Provided full-year 2025 revenue guidance of $61.0 to $64.0 billion

### Strategic Moves
- **Pipeline Expansion**: Continued investment in obesity and oncology therapeutics
- **Post-COVID Strategy**: Successful transition to diversified pharmaceutical portfolio

## SWOT Analysis

### Strengths
- **Strong Financial Performance**: 7% operational growth in 2024 with robust Q4 results
- **Diversified Pipeline**: Robust portfolio spanning oncology, obesity, and mRNA therapeutics
- **Strategic Acquisitions**: $43 billion Seagen acquisition significantly enhances oncology capabilities
- **Attractive Dividend**: 6.61% dividend yield provides strong shareholder returns

### Weaknesses
- **COVID Revenue Dependence**: Still includes COVID-19 product revenues in 2025 guidance
- **High Acquisition Costs**: $43 billion Seagen acquisition represents significant capital deployment
- **Pipeline Risk**: Early and mid-stage assets carry development and regulatory risks

### Opportunities
- **Obesity Market**: Growing obesity treatment market with GLP-1 and amylin development
- **Oncology Expansion**: Seagen acquisition provides access to expanding cancer treatment market
- **mRNA Applications**: Broader therapeutic applications beyond COVID-19 through BioNTech partnership

### Threats
- **Regulatory Challenges**: Drug development subject to regulatory approval risks
- **Competitive Pressure**: Intense competition in obesity and oncology markets
- **Patent Expirations**: Potential revenue impact from patent cliff on existing products

## Key Metrics Summary

| Metric | Value | Period |
|--------|--------|---------|
| **Financial Performance** |
| Revenue | $63.6B | Full Year 2024 |
| Revenue Growth | 7% | YoY Operational 2024 |
| Q4 Revenue | $17.8B | Q4 2024 |
| Q4 Growth | 22% | YoY Q4 2024 |
| Revenue (TTM) | $62.78B | Current |
| EPS (TTM) | $1.72 | Current |
| **Market Metrics** |
| Market Cap | $148.00B | Current |
| 52-Week High | $27.21 | Current |
| 52-Week Low | $19.83 | Current |
| **Valuation** |
| P/E Ratio (TTM) | 15.13 | Current |
| Forward P/E | 8.67 | Current |
| PEG Ratio | 3.77 | Current |
| Price/Book | 1.59 | Current |
| Dividend Yield | 6.61% | Current |
| **Guidance** |
| 2025 Revenue Guidance | $61.0-$64.0B | Full Year 2025 |
| **Corporate** |
| Employees | 88,000+ | Current |
| Founded | 1849 | Historical |
| Exchange | NYSE (PFE) | Current |

*Sources: Yahoo Finance, Pfizer earnings reports, Macrotrends, Statista*

---

## Sources

- [Pfizer Reports Strong Q4 and Full-Year 2024 Results](https://insights.pfizer.com/fourth-quarter-fy-earnings-2024)
- [[PDF] Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 ...](https://s206.q4cdn.com/795948973/files/doc_financials/2024/q4/Q4-2024-PFE-Earnings-Release-Final.pdf)
- [Pfizer revenue 2006-2024 - Statista](https://www.statista.com/statistics/266171/revenue-of-pfizer-since-2006/?srsltid=AfmBOop8hEEYPCuIpQhmg1HgEtAlfqEMNL47dP8lw9kFyTlgSCWihkke)
- [Pfizer Revenue 2011-2025 | PFE - Macrotrends](https://www.macrotrends.net/stocks/charts/PFE/pfizer/revenue)
- [Pfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year ...](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-full-year-2025-guidance-and-reaffirms-full)
- [New Drug Development Pipeline - Pfizer](https://www.pfizer.com/science/drug-product-pipeline)
- [Why Pfizer's Post-COVID Future Looks Brighter Than Ever](https://finance.yahoo.com/news/why-pfizers-post-covid-future-172800014.html)
- [Why Pfizer's Post-COVID Future Looks Brighter Than Ever](https://www.fool.com/investing/2025/09/28/why-pfizers-post-covid-future-looks-brighter-than/)
- [Pfizer's CFO on building a post-Covid future and how it won the fight ...](https://sherwood.news/markets/pfizers-cfo-on-building-a-post-covid-future-and-how-it-won-the-fight-for/)
- [Our portfolio | Pfizer](https://www.pfizer.com/partners/venture-investments/our-portfolio)
- [Pfizer Completes Acquisition of Seagen](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-completes-acquisition-seagen)
- [Pfizer Invests $43 Billion to Battle Cancer](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer)
- [Pfizer's $43B buyout of ADC specialist Seagen is a done deal](https://www.fiercepharma.com/pharma/done-deal-pfizer-completes-43b-acquisition-seagen-doubling-its-oncology-pipeline)
- [Pfizer gets OK for $43-billion Seagen deal after donating cancer ...](https://www.reuters.com/markets/deals/pfizer-gets-ok-43-bln-seagen-deal-after-donating-cancer-drug-rights-2023-12-12/)
- [Pfizer Completes $43 Billion Acquisition of Seagen - FTI Consulting](https://www.fticonsulting.com/insights/success-stories/pfizer-completes-43-billion-acquisition-seagen)
- [Oncology: Cancer Drug Pipeline and Clinical Trials - Pfizer](https://www.pfizer.com/science/oncology-cancer/pipeline)
- [New Drug Development Pipeline - Pfizer](https://www.pfizer.com/science/drug-product-pipeline)
- [Overview - by Cancer | Pfizer Oncology Development Website](https://www.pfizeroncologydevelopment.com/)
- [[PDF] 1 - Pfizer Pipeline](https://cdn.pfizer.com/pfizercom/product-pipeline/Pipeline_Update_04FEB2025.pdf?VersionId=uLH0GvYiQQ5ovLs6eCxf0ZluTI3FZh_f)
- [Explore Our Cancer (Oncology) Clinical Trials | Pfizer](https://www.pfizerclinicaltrials.com/our-research/oncology)
